These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 35656754)
1. Effects of Renal Impairment on the Pharmacokinetics of Gefapixant, a P2X3 Receptor Antagonist. Nussbaum JC; Hussain A; Min KC; Marbury TC; Lasseter K; Stoch SA; Iwamoto M J Clin Pharmacol; 2022 Nov; 62(11):1435-1444. PubMed ID: 35656754 [TBL] [Abstract][Full Text] [Related]
2. Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial. Smith JA; Kitt MM; Morice AH; Birring SS; McGarvey LP; Sher MR; Li YP; Wu WC; Xu ZJ; Muccino DR; Ford AP; Lancet Respir Med; 2020 Aug; 8(8):775-785. PubMed ID: 32109425 [TBL] [Abstract][Full Text] [Related]
3. Assessment of the Effect of Pyrimethamine, a Potent Inhibitor of Multidrug and Toxin Extrusion Protein 1/2K, on the Pharmacokinetics of Gefapixant (MK-7264), a P2X3 Receptor Antagonist. Nussbaum JC; Hussain A; Ma B; Min KC; Evers R; Li Y; Garrett G; Stoch SA; Iwamoto M Clin Pharmacol Drug Dev; 2022 Jan; 11(1):123-128. PubMed ID: 34145987 [TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetic analysis of the P2X3-receptor antagonist gefapixant. Chawla A; Largajolli A; Hussain A; Kleijn H; Ait-Oudhia S; Anton J; Krishna Ananthula H; Nussbaum J; La Rosa C; Gheyas F CPT Pharmacometrics Syst Pharmacol; 2023 Aug; 12(8):1107-1118. PubMed ID: 37147897 [TBL] [Abstract][Full Text] [Related]
5. Safety, Pharmacodynamics, and Pharmacokinetics of P2X3 Receptor Antagonist Eliapixant (BAY 1817080) in Healthy Subjects: Double-Blind Randomized Study. Friedrich C; Francke K; Gashaw I; Scheerans C; Klein S; Fels L; Smith JA; Hummel T; Morice A Clin Pharmacokinet; 2022 Aug; 61(8):1143-1156. PubMed ID: 35624408 [TBL] [Abstract][Full Text] [Related]
6. Assessment of Pharmacokinetic Interaction Between Gefapixant (MK-7264), a P2X3 Receptor Antagonist, and the OATP1B1 Drug Transporter Substrate Pitavastatin. McCrea JB; Hussain A; Ma B; Garrett GC; Evers R; Laabs JE; Stoch SA; Iwamoto M Clin Pharmacol Drug Dev; 2022 Mar; 11(3):406-412. PubMed ID: 34821075 [TBL] [Abstract][Full Text] [Related]
7. Update on the clinical development of gefapixant, a P2X3 receptor antagonist for the treatment of refractory chronic cough. Muccino D; Green S Pulm Pharmacol Ther; 2019 Jun; 56():75-78. PubMed ID: 30880151 [TBL] [Abstract][Full Text] [Related]
8. Single- and Multiple-Dose Pharmacokinetics of Gefapixant (MK-7264), a P2X3 Receptor Antagonist, in Healthy Adults. Nussbaum JC; Hussain A; Butera P; Ford AP; Kitt MM; O'Neill EA; Smith S; Vargas G; O'Reilly T; Wynne C; Stoch SA; Iwamoto M J Clin Pharmacol; 2024 Aug; 64(8):1023-1029. PubMed ID: 38651193 [TBL] [Abstract][Full Text] [Related]
9. Characterization of the absorption, metabolism, excretion, and mass balance of gefapixant in humans. Nussbaum JC; Hussain A; Ma B; Min KC; Chen Q; Tomek C; Iwamoto M; Stoch SA Pharmacol Res Perspect; 2022 Feb; 10(1):e00924. PubMed ID: 35106949 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of gefapixant, a P2X McGarvey LP; Birring SS; Morice AH; Dicpinigaitis PV; Pavord ID; Schelfhout J; Nguyen AM; Li Q; Tzontcheva A; Iskold B; Green SA; Rosa C; Muccino DR; Smith JA; Lancet; 2022 Mar; 399(10328):909-923. PubMed ID: 35248186 [TBL] [Abstract][Full Text] [Related]
11. BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration. Garceau D; Chauret N Pulm Pharmacol Ther; 2019 Jun; 56():56-62. PubMed ID: 30902655 [TBL] [Abstract][Full Text] [Related]
12. The effect of gefapixant, a P2X3 antagonist, on cough reflex sensitivity: a randomised placebo-controlled study. Morice AH; Kitt MM; Ford AP; Tershakovec AM; Wu WC; Brindle K; Thompson R; Thackray-Nocera S; Wright C Eur Respir J; 2019 Jul; 54(1):. PubMed ID: 31023843 [TBL] [Abstract][Full Text] [Related]
13. The discovery and development of gefapixant. Ford AP; Dillon MP; Kitt MM; Gever JR Auton Neurosci; 2021 Nov; 235():102859. PubMed ID: 34403981 [TBL] [Abstract][Full Text] [Related]
14. The discovery and development of gefapixant as a novel antitussive therapy. Matera MG; Rogliani P; Page CP; Calzetta L; Cazzola M Expert Opin Drug Discov; 2024 Oct; 19(10):1159-1172. PubMed ID: 39138872 [TBL] [Abstract][Full Text] [Related]
15. Gefapixant: First Approval. Markham A Drugs; 2022 Apr; 82(6):691-695. PubMed ID: 35347635 [TBL] [Abstract][Full Text] [Related]
16. A Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of 3 Weeks of Orally Administered Gefapixant in Healthy Younger and Older Adults. Nussbaum J; Hussain A; Ford A; Butera P; Kitt M; Smith S; Stoch A; Iwamoto M Lung; 2022 Jun; 200(3):315-323. PubMed ID: 35670873 [TBL] [Abstract][Full Text] [Related]
17. A phase 3, randomized, double-blind, clinical study to evaluate the long-term safety and efficacy of gefapixant in Japanese adult participants with refractory or unexplained chronic cough. Niimi A; Sagara H; Kikuchi M; Arano I; Sato A; Shirakawa M; La Rosa C; Muccino D Allergol Int; 2022 Oct; 71(4):498-504. PubMed ID: 35752582 [TBL] [Abstract][Full Text] [Related]
18. Clinical Formulation Bridging of Gefapixant, a P2X3-Receptor Antagonist, for the Treatment of Chronic Cough. Gupta P; Hussain A; Ford AP; Smith S; Nussbaum JC; Stoch A; Iwamoto M Clin Pharmacol Drug Dev; 2022 Sep; 11(9):1054-1067. PubMed ID: 35510785 [TBL] [Abstract][Full Text] [Related]
19. The Efficacy and Safety of Gefapixant in a Phase 3b Trial of Patients with Recent-Onset Chronic Cough. McGarvey L; Sher M; Shvarts YG; Lu S; Wu WC; Xu P; Schelfhout J; La Rosa C; Nguyen AM; Reyfman PA; Afzal AS Lung; 2023 Apr; 201(2):111-118. PubMed ID: 36879087 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, Safety, and Tolerability of Intravenous Durlobactam and Sulbactam in Subjects with Renal Impairment and Healthy Matched Control Subjects. O'Donnell J; Preston RA; Mamikonyan G; Stone E; Isaacs R Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31307978 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]